The aim of this study was to evaluate the expression of matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) in prostate cancer in the main tumor mass and tumor cells at the positive margin as well as the influence of these biomarkers on the biochemical recurrence of the disease in prostatectomy patients. Tissue microarrays of 120 archival prostate carcinoma samples were immunohistochemically evaluated for MMP-2 and MMP-9 expression and compared with clinicopathological parameters. Tumors with positive surgical margins showed significantly higher overall expression of MMP-9 versus tumors with negative resection marginsP=0.0121. MMP-9 expression was significantly elevated in tumors from patients who had biochemical recurrenceP=0.0207. In the group of patients with negative margins, MMP-9 expression above the cut-off value was significantly associated with recurrenceP=0.0065. Multivariate analysis indicated that MMP-9 is a good predictor of biochemical recurrence (odds ratio = 10.29;P=0.0052). Expression of MMP-2 in tumor cells was significantly higher at the positive margins than in the main tumor massP=0.0301. The present results highlight the potential value of MMP-2 and MMP-9 expression for predicting the behavior of prostate tumors after prostatectomy with both positive and negative surgical margins.

Prostate cancer (Pca) is among the most common malignant diseases in men and the fourth leading cause of death worldwide. Surgery and radical radiotherapy (RT) remain the gold standard for the treatment of localized or locally advanced prostate cancer. The efficiency of radiotherapy treatment is limited by toxic side effects due to dose escalation. Cancer cells often develop radio-resistant mechanisms that are related to the DNA repair, inhibition of apoptosis or changes in cell cycle. Based on our earlier research on biomarkers that are involved in those cellular mechanisms (p53, bcl-2, NF-kb, Cripto-1 and Ki67 proliferation) and correlation with clinico-pathological parameters (age, PSA value, Gleason score, grade group, prognostic group), we created the numerical index for risk of tumor progression in patients with radioresistant tumors. For each of these parameters, the strength of association with disease progression was statistically assessed, and a specific number of points was assigned proportional to the strength of the correlation. Statistical analysis identified an optimal cut-off score of 22 or more as an indicator of significant risk for progression with a sensitivity of 91.7% and a specificity of 66.7%. The scoring system in the retrospective receiver operating characteristic analysis showed AUC of 0.82. The potential value of this scoring is the possibility of identifying patients with clinically significant radioresistant Pca.

Rak prostate najčešći je malignom u muškaraca u Europi i SAD-u, raznolik u kliničkoj prezentaciji, patohistološkoj slici, obrascima rasta i širenja. Kada se rak prostate otkrije u ranom stadiju postotak izlječenja je visok....

Wir berichten über einen Fall des Bellini-Gang-Karzinoms, das sich bei dem 37-jährigen Patienten zunächst als eine metastatische Erkrankung der paraaortalen Lymphknoten manifestierte, ohne deutlichen röntgenologischen Befund im Sinne eines Nierentumors. Auch der zytologische Befund war nicht typisch für einen Nierentumor. Der Tumor erfüllte sowohl makroskopisch als auch mikroskopisch die von Sringly u. Mitarb. vorgeschlagenen Major- und Minor-Kriterien, jedoch fand sich bei der Immunohistochemie keine Zellenaffinität für UEA-1, die sonst, gemäß den Literaturangaben, auf typische Weise den Ursprung des Tumors aus den Bellini-Gängen bestätigt. Diese eher seltene Tumorerkrankung, überwiegend bei jüngeren Menschen vorkommend, stellt mit ihrem aggressiven klinischen Verlauf nach wie vor ein diagnostisches und therapeutisches Problem dar. Trotz aggressiver chirurgischer, strahlentherapeutischer und immunotherapeutischer Maßnahmen war der Verlauf der Erkrankung in unserem Fall, wie auch in der Mehrzahl der veröffentlichten Fälle, äußerst ungünstig. A 37-year-old male patient presented with a Bellini duct carcinoma, at first as a metastatic illness of the paraaortal lymph nodes, without significant radiologic signs of a kidney tumor. Cytological diagnostics did not recognize this tumor. Macroscopically and microscopically the tumor fulfilled the major and minor criteria of Sringly et al., but immunohistochemical findings did not show cell affinity for UEA-1, which, according to the literature, typically confirms its origin from Bellini ducts. This rare neoplasm, primarily found in a younger population, still represents a diagnostic and therapeutical challenge as a result of its aggressive clinical course. In our patient, as in the majority of cases presented in the literature, tumor prognosis was very poor, in spite of aggressive surgical, radium and immune therapy.